BioLineRx Ltd (NASDAQ:BLRX) Q2 2020 Earnings Conference Call - Final Transcript
Aug 06, 2020 • 10:00 am ET
Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Second Quarter 2020 Results Conference Call. [Operator Instructions]
I would now like to turn the call over to Timothy McCarthy of LifeSci Advisors to read the safe harbor statement. Tim, please go ahead.
Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements in this conference call, other than historical facts, are indeed forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project and other similar expressions are used typically to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other factors that may affect BioLineRx's business, financial condition and other operating results. These include, but are not limited to, the risk factors and other qualifications contained in BioLineRx' annual report on Form 20-F, quarterly reports filed in the 6-K and other reports filed by BioLineRx with the SEC, to which your attention is directed. Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. BioLineRx expressly disclaims any intent or obligation to update these forward-looking statements.
At this time, it is now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BioLineRx.
Philip A. Serlin
Thank you, Tim, and good morning, everyone. And thank you for joining us on our second quarter earnings conference call today. Earlier this morning, we issued our Q2 results press release, a copy of which is available in the Investor Relations section of our website. It was also filed as a 6-K.
I will begin with some brief prepared remarks, and Mali Zeevi, our Chief Financial Officer, will provide a short discussion of our financial results. We will then open up the call to your questions. Also joining the call for Q&A are Abi Vainstein, our Vice President, Clinical Development; and Ella Sorani, our Vice President, Research and Development.
During the second quarter, we continued to advance our clinical programs towards important and meaningful data readouts that are anticipated over the next few months. And while some timelines have changed very modestly as a result of COVID-19 and other factors, we look forward to a catalyst-rich second half of the year from motixafortide, formerly known as BL-8040, our lead clinical candidates.
Recall that motixafortide is currently being evaluated in multiple late-stage trials across a range of cancer indications. At this point, I will provide an update on our motixafortide development programs as well as our second clinical candidate, the anti-cancer vaccine, AGI-134.
Beginning with late-stage pancreatic cancer, or PDAC, recall that we are currently evaluating motixafortide in combination with KEYTRUDA and chemotherapy in a Phase IIa clinical trial, known as the COMBAT/KEYNOTE-202 trial under a clinical trial collaboration with Merck.
As you probably know, PDAC is among the most difficult cancers to treat and patients with this diagnosis have historically had